The global Ovarian Cancer Drugs Market size is expected to be valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.
Ovarian
cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all
femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and
140,000 deaths worldwide in 2016 with the highest incidence being reported in
North America and Europe.
Introduction
of non-platinum based PARP inhibitors and VEGF inhibitors in second and
third-line settings has changed the treatment regime for ovarian cancer
dramatically. Several biologic and small-molecule therapies including antibody
drug conjugates (ADC) in development are estimated to have a major impact on
ovarian cancer treatment spectrum.
Request a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-drugs-market
Further key findings from the report suggest:
- EU5 is
projected to be the second largest market with more than 10.0% share in
2022, owing to increasing ovarian cancer incidence and approval of PARP
inhibitors
- Key players
in the industry are focusing on collaborations for development, broader
product portfolios, and regional expansion in emerging markets to increase
their market share
- Combination
regimens and pipeline breakthroughs, specifically those including
checkpoint inhibitors such as Roche’s Tecentriq and Pfizer’s Bavencio, are
poised to be the upcoming milestones for ovarian cancer treatment
- PARP
inhibitors are anticipated to be the fastest growing drug class in the
ovarian cancer market through the forecast period. Factors such as
continued uptake of approved PARP inhibitors owing to their superior
efficacy, long treatment duration, and considerable number of treatment
opportunities in first-line advanced settings are likely to propel the
growth of the drug class.
- Although
angiogenesis inhibitors accounted for the majority of shares in the market
in 2016, the drug class is expected to capture a marginal share in 2022
owing to increasing competition from PARP inhibitors and novel pipeline
products
- Out of 78
drugs in the pipeline for ovarian cancer, 11 drugs are in Phase III, 29 in
Phase II and the remaining in Phase I and pre-clinical trials
- A greater
understanding of tumor microenvironment is estimated to occur, which would
further drive successful development of new patient-specific therapies
through the forecast period
- Late-stage
pipeline includes novel drugs such as ImmunoGen’s mirvetuximab
soravtansine and Vascular Biogenics’ VBL-111.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment